Is pretreatment hemoglobin level a predictor of complete response to salvage chemotherapy for recurrent platinum-pretreated ovarian carcinoma?

European Journal of Gynaecological Oncology

Volumn 24, Issue 5, 2003, Pages 405-410

  Gadducci, A ^a,c   Cosio, S ^a   Fanucchi, A ^a   Tanganelli, L ^b   Conte, P F ^b   Cristofani, R ^c   Genazzani, A R ^a  

^a Div of Gynecology and Obstetrics   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Hemoglobin; Platinum; Recurrent ovarian carcinoma; Second line chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREDICTION; PROGNOSIS; RECURRENT CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; FEMALE; HEMOGLOBINS; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0141918484     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y. et al.: "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer". N. Engl. J. Med., 1996, 334, 1.
2. McGuire W. P., Ozols R. F.: "Chemotherapy of advanced ovarian cancer". Semin. Oncol., 1998, 25, 340.
3. Conte P. F., Cianci C., Gadducci A.: "Up date in the management of advanced ovarian carcinoma". Crit. Rev. Oncol. Hematol., 1999, 32, 49.
4. García A. A.: "Salvage therapy for ovarian cancer". Curr. Oncol. Rep., 1999, 1, 64.
5. Piccart M. J., Du Bois A., Gore M. E., Neijt J. P., Pecorelli S., Pujade-Lauraine E.: "A new standard of care for treatment of ovarian cancer". Eur. J. Cancer, 2000, 36, 10.
6. Piccart M. J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., Stuart G. et al.: "Randomized" intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results". J. Natl. Cancer Inst., 2000, 92, 699.
7. Neijt J. P., Engelholm S. A., Tuxen M. K., Sorensen P. G., Hansen M., Sessa C. et al.: "Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer". J. Clin. Oncol., 2000, 18, 3084.
8. Ozols R. F.: "Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer". Semin. Oncol., 2000, 27 (suppl. 7), 3.
9. Gadducci A., Conte P. F., Cianci C., Negri S., Genazzani A. R.: "Treatment options in patients with recurrent ovarian cancer". Anticancer Res., 2001, 21, 3557.
10. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S. et al.: "Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin". J. Clin. Oncol., 1991, 9, 389.
11. Trimble E. L., Adams J. D., Vena D., Hawkins M. J., Friedman M. A., Fisherman J. S. et al.: "Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103". J. Clin. Oncol., 1993, 11, 2405.
12. Eisenhauer E. A., ten Bokkel Huinink W. W., Swenerton K. D., Gianni L., Myles J., van der Burg M. E. et al.: "European-Canadian trial of paclitaxel in relapsed ovarian cancer: high versus low-dose and long versus short infusion". J. Clin. Oncol., 1994, 12, 2654.
13. Gadducci A., Brunetti I., Muttini M. P., Fanucchi A., Dargenio F., Giannessi P. G., Conte P. F.: "Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer". Eur. J. Cancer, 1994, 30, 1432.
14. Vermorken J. B., Kobierska A., van der Burg M. E., Chevallier B., Zanaboni F., ten Bokkel Huinink W. W. et al.: "High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience". Eur J. Gynaecol. Oncol., 1995, 16, 433.
15. Chollet P., Bensmaine M. A., Brienza S., Deloche C., Cure H., Caillet H., Cvitkovic E.: "Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer". Am. Oncol., 1996, 7, 1065.
16. Lund B., Neijt J. P.: "Gemcitabine in cisplatin-resistant ovarian cancer". Semin. Oncol., 1996, 23 (suppl. 10), 72.
17. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I. et al.: "Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer". J. Clin. Oncol., 1997, 15, 2183.
18. Muggia F. M., Hainsworth J. D., Jeffers S., Miller P., Groshen S., Tan M. et al.: "Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation". J. Clin. Oncol., 1997, 15, 987.
19. Trope C., Hogberg T., Kaern J., Bertelsen K., Bjorkholm E., Boman K. et al.: "Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience". Ann. Oncol., 1998, 9, 1301.
20. Bolis G., Parazzini F., Scarfone G., Villa A., Amoroso M., Polatti A. et al.: "Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol. Oncol., 1999, 72, 60.
21. Silver D. F., Piver M. S.: "Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum". Am. J. Clin. Oncol., 1999, 22, 450.
22. Colombo N., Parma G., Bocciolone L., Sideri M., Franchi D., Maggioni A.: "Role of chemotherapy in relapsed ovarian cancer". Crit. Rev. Oncol. Hematol., 1999, 32, 221.
23. Gordon A. N., Fleagle J. T., Guthrie D., Parkin D. E., Gore M., Lacave A. J., Mutch D.: "Interim analysis of a phase III randomized trial of Doxil/Caelyx (D) versus topotecan (T) in the treatment of patients with relapsed ovarian cancer". Proc. Am. Soc. Clin. Oncol., 2000, 19, 380, (abstract 1504).
24. McGuire W. P., Blessing J. A., Bookman M. A., Lentz S. S., Dunton C. J.: "Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study". J. Clin. Oncol., 2000, 18, 1062.
25. Piccart M. J., Green J. A., Jimenez Lacave A., Reed N., Vergote I., Benedetti-Panici P. et al.: "Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group". J. Clin. Oncol., 2000, 18, 1193.
26. Verschraegen C. F., Sittisomwong T., Kudelka A. P., Guedes E., Stager M., Nelson-Taylor T. et al.: "Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma". J. Clin. Oncol., 2000, 18, 2733.
27. Katsumata N., Tsunematsu R., Tanaka K., Terashima Y., Ogita S., Hoshiai H. et al.: "A phase II trial of docetaxel in platinum pretreated patients with advanced epithelial ovarian cancer: a Japanese cooperative study". Ann. Oncol., 2000, 11, 1531.
28. Gordon A. N., Granai C. O., Rose P. G., Hainsworth J., Lopez A., Weissman C. et al.: "Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer". J. Clin. Oncol., 2000, 18, 3093.
29. Thigpen J. T., Vance R. B., Khansur T.: "Second-line chemotherapy for recurrent carcinoma of the ovary". Cancer, 1993, 71, 1559.
30. Markman M., Bookman M. A.: "Second-line treatment of ovarian cancer". The Oncologist, 2000, 5, 26.
31. Shamsunder S., Kumar L., Gupta S., Kumar S., Bhatla N., Singh R., Kochupillai V.: "Chemotherapy in recurrent epithelial ovarian cancer (EOC): an analysis of prognostic factors". J. Obstet. Gynaecol. Res., 2000, 26, 215.
32. Eisenhauer E. A., Vermorken J. B., van Glabbeke M.: "Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients". Ann. Oncol., 1997, 8, 963.
33. Safra T., Groshen S., Jeffers S., Tsao-Wei D. D., Zhou L., Muderspach L. et al.: "Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome". Cancer 2001, 91, 90.
34. Vaupel P., Thews O., Hoeckel M.: "Treatment resistance of solid tumors:role of hypoxia and anemia". Med. Oncol., 2001, 18, 243.
35. Groopman J. E., Itri L. M.: "Chemotherapy-induced anemia in adults: incidence and treatment". J. Natl. Cancer Inst., 1999, 91, 1616.
36. Hensley M. L., Lebeau D., Leon L. F., Venkatraman E., Waltzman R., Sabbatini P. et al.: "Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer". Gynecol. Oncol., 2001, 81, 485.
37. Obermair A., Handisurya A., Kaider A., Sevelda P., Kolbl H., Gitsch G.: "The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: a prospective review". Cancer, 1998, 83, 726.
38. Peethambaram P. P., Long H. J.: "Second-line and subsequent therapy for ovarian carcinoma". Curr. Oncol. Rep., 2002, 4, 159.